Abstract
The demethylation agent 5-azacytidine (5-aza) is often used to induce the cardiomyogenic differentiation of mesenchymal stem cells (MSCs). Due to the poor stability of 5-aza, it hydrolyzes into two intermediate products, N-(formylamidino)-N′-β-D-ribofuranosylurea and 1-β-D-ribofuranosyl-3-guanylurea within days in a physiological environment. However, the effects of these intermediate products on the differentiation of MSCs into cardiomyocytes have not been investigated. The aim of this study was to elucidate the effects these hydrolysis products on the differentiation of MSCs into cardiomyocytes. The preliminary results reveal that MSCs treated with hydrolyzed 5-aza exhibited a higher differentiation ratio of MSCs into cardiomyocytes, as evidenced by cardiac marker expressions (assessed by gene expression assay, immunofluorescence staining, and flow cytometry assays) after short incubation compared to that for untreated MSCs. These results suggest that the efficiency of the cardiomyogenic differentiation of MSCs can be enhanced by treating the cells with hydrolyzed 5-aza.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
